Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Exelixis has started the dose-escalation stage of a Phase […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Daiichi Sankyo and MSD expand collaboration on ADC development Daiichi Sankyo and MSD have expanded their partnership to globally develop and commercialize three DXd antibody-drug conjugates, including […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Exelixis drops tissue factor-targeting ADC after deciding it’s no match for Tivdak Exelixis has decided to discontinue development of its tissue factor-targeting antibody-drug conjugate, XB002, after assessing […]
Weekly Digest – August 2024 Weekly Digest – August 2024 05 Aug 2024: Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors Salubris Biotherapeutics has received EMA […]
